Not admitted · Third-party claim
Rules 1.1.0 · as of 14 Sep 2026
Owen Scott Muir · Said 9 Dec 2024 · owen-1397
Quote
Third-party claim
“Johnson & Johnson’s branded esketamine (note the prefix es ) is on track to reach coveted “blockbuster status.””
Guest essay by Ben Spielberg (founder of Bespoke Treatment), narrated by the author, on why ketamine clinics keep closing. Section 'Spravato: Coming In Hot': J&J's esketamine (Spravato, FDA approved for MDD in 2019) is said to be on track for blockbuster status; he reports his clinic's ketamine infusion census fell over 70% as insured Spravato ($20 copay) took share.
A quoted or paraphrased claim by someone else that the author does not adopt as their own.